🇺🇸 Regeneron Casirivimab + Imdevimab in United States

10 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Agitation — 1 report (10%)
  2. Blood Pressure Increased — 1 report (10%)
  3. Chest X-Ray Abnormal — 1 report (10%)
  4. Cough — 1 report (10%)
  5. Dizziness — 1 report (10%)
  6. Dry Mouth — 1 report (10%)
  7. Dyspnoea — 1 report (10%)
  8. Haemoptysis — 1 report (10%)
  9. Lung Opacity — 1 report (10%)
  10. Nausea — 1 report (10%)

Source database →

Other Infectious Disease / Virology approved in United States

Frequently asked questions

Is Regeneron Casirivimab + Imdevimab approved in United States?

Regeneron Casirivimab + Imdevimab does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Regeneron Casirivimab + Imdevimab in United States?

Erin McCreary is the originator. The local marketing authorisation holder may differ — check the official source linked above.